VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 1409 · 115th Congress

Cancer Drug Parity Act of 2017

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

LLR LanceSponsor
175 cosponsors · 90 D, 85 R
MBR Blackburn ECD Cummings KCD Clark BCR Carter BCR Comstock PDD DeFazio DDR Donovan BFD Foster BFR Flores BGR Guthrie JGD Garamendi BHD Higgins GHR Harper PKR King DKD Kildee DKD Kilmer RLR Latta BLR Long TMR Murphy SMD Maloney TMR MacArthur TPR Poe CPD Pingree MPD Pocan TRD Ryan PSR Sessions ESD Swalwell DWD Wasserman Schultz RWR Wittman SDR DesJarlais RGD Grijalva JSD Speier JFR Fortenberry HGR Griffith SPD Peters FSR Sensenbrenner EBD Blumenauer JKD Kennedy DMR McKinley RGD Gallego JYD Yarmuth BBD Boyle ABR Biggs MCD Cartwright KCR Cramer BJR Johnson ZLD Lofgren SMD Moulton SPR Palazzo LSR Smucker DYR Young SBD Bonamici DBR Bacon RFR Frelinghuysen LGD Gutiérrez JLD Langevin GBR Bilirakis CBD Bustos MCR Coffman TKR Kelly BMD McCollum DPD Price JSD Sarbanes KYR Yoder RDD DeLauro RDR Davis BLD Luján MMR McCaul MBR Bishop CDR Dent AHD Hastings JLD Lewis DLD Lipinski BMR Mast LFD Frankel RHR Hudson SBR Brooks JHD Huffman PMR Mitchell LSD Slaughter SDR Duffy JDD Delaney BOD O’Rourke STR Tipton GGR Grothman DLD Loebsack DBR Black GCD Connolly JCD Chu JHD Himes JHR Hice TSD Suozzi MTR Turner DTR Trott SSR Stivers MTD Takano JBR Bergman SCD Cohen RCR Costello BFR Fitzpatrick VHR Hartzler GND Napolitano ASD Schiff CSD Shea-Porter GTR Thompson PTD Tonko MDD Doyle CHR Higgins WJR Jones END Norton RBD Brady JCR Culberson JPD Panetta TYR Yoho MGR Gallagher SJD Jackson Lee JKR Katko MLD Lujan Grisham LBR Bucshon AED Eshoo PJD Jayapal POR Olson YCD Clarke TGR Graves DMD Matsui IRR Ros-Lehtinen EED Engel AFR Ferguson CHD Hanabusa RHR Hultgren SLD Lynch BLR Loudermilk TWR Walberg TWD Walz BLD Lawrence CSR Smith DCR Collins DJR Joyce JRD Raskin BSD Schneider JGR González-Colón WKD Keating RKD Khanna TOD O’Halleran LRD Roybal-Allard ASR Scott ESR Stefanik FUR Upton MAR Amodei ECD Cleaver JRR Renacci TGR Gowdy BRD Rush CMR McMorris Rodgers DPD Payne BPR Poliquin KRD Rice DED Evans DRR Reichert RKD Kihuen BLR Luetkemeyer JMD McGovern VGD Gonzalez GGR Gianforte CMD Maloney RNR Norman TLD Lieu DYR Young TDD Deutch JRR Rutherford AAD Adams ABD Bera MDD DeSaulnier JLD Larson SMD Murphy

29 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.

What it does: CRS summary · Introduced in House · Mar 7, 2017

Cancer Drug Coverage Act of 2017

This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Cancer Drug Parity Act of 2017

Latest action (Mar 17, 2017): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Mar 7, 2017

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.